A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Must have received: systemic treatment regimen

have failed, or been intolerant to any approved therapy and had received at least two systemic treatment regimens in Part 1; and at least one systemic treatment regimen in Part 2

Cannot have received: loncastuximab tesirine (loncastuximab tesirine)

Previous therapy with loncastuximab tesirine

Cannot have received: polatuzumab vedotin (polatuzumab vedotin)

Exception: applies to Arm C only

Participants who received previous treatment of polatuzumab vedotin containing regimen will be excluded from Arm C

Cannot have received: glofitamab (glofitamab)

Exception: applies to Arm E only

Participants who received previous treatment of glofitamab containing regimen will be excluded from Arm E

Cannot have received: mosunetuzumab (mosunetuzumab)

Exception: applies to Arm F only

Participants who received previous treatment of mosunetuzumab containing regimen will be excluded from Arm F

Cannot have received: CAR-T cell therapy

Exception: within 100 days prior to C1D1; primary refractory patients (progressive or persistent disease within 30 days) to CAR-T-cell therapy are not eligible

Prior treatment with CAR-T-cell therapy within 100 days prior to C1D1; primary refractory patients (progressive or persistent disease within 30 days) to CAR-T-cell therapy are not eligible

Cannot have received: allogeneic stem cell transplant

Exception: applies to Arms E and F only

Prior allogeneic stem cell transplant and solid organ transplant

Cannot have received: autologous stem cell transplant

Exception: within 100 days prior to C1D1; applies to Arms E and F only

Autologous stem cell transplant within 100 days prior to C1D1

Cannot have received: polatuzumab vedotin, glofitamab, or mosunetuzumab (polatuzumab vedotin, glofitamab, mosunetuzumab)

Exception: applied to relevant arm and/or cohort of the specific drug administered

Previous treatment with polatuzumab vedotin, glofitamab or mosunetuzumab (applied to relevant arm and/or cohort of the specific drug administered)